Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
Validated PROMs can assist in providing high-quality care and improve a patient’s overall experience.
Men with metastatic castration-resistant prostate cancer with predominantly bone metastases who receive more than 4 dose of radium-223 have significantly improved overall survival than those who receive 4 or fewer doses, a study found.
Phase 2 trial results suggests abiraterone used in combination in cabazitaxel in men with chemotherapy-naïve metastatic castration-resistant prostate cancer might prolong radiographic progression-free survival compared with abiraterone alone.
In a study of men with metastatic castration-resistant prostate cancer, sipuleucel-T immunotherapy used at any point during treatment was associated with a decreased risk of death compared with utilization of newer oral androgen pathway inhibitors therapy without sipuleucel-T.
In a small study, intermittent vs continuous dosing was associated with improved overall survival and prolonged time on treatment.
A new analysis of men in the CARD study showed that cabazitaxel improved pain response and decreased the likelihood of pain progression compared with either abiraterone or enzalutamide.
Investigators found that men treated with 5-alpha-reductase inhibitors are not more likely to die from prostate cancer or any other cause.
Despite the introduction in recent year of promising novel agents, men with newly diagnosed metastatic prostate cancer have experienced only a slight decline in death risk.
Bone imaging cannot be safely omitted in advanced prostate cancer cases because no PSA level combined with T stage and Gleason Grade Group can accurately rule in bone metastases, a new study found.